A stromal gene signature associated with inflammatory breast cancer

The factors that determine whether a breast carcinoma will develop into inflammatory breast cancer (IBC) remain poorly understood. Recent evidence indicates that the tumor stroma influences cancer phenotypes. We tested the hypotheses that the gene expression signature of the tumor stroma is a distinctive feature of IBC. We used laser capture microdissection to obtain enriched populations of tumor epithelial cells and adjacent stromal cells from 15 patients with IBC and 35 patients with invasive, noninflammatory breast cancer (non‐IBC). Their mRNA expression profiles were assessed using Affymetrix GeneChips™. In addition, a previously established classifier for IBC was evaluated for the resulting data sets. The gene expression profile of the tumor stroma distinguished IBC from non‐IBC, and a previously established IBC prediction signature performed better in classifying IBC using the gene expression profile of the tumor stroma than it did using the profile of the tumor epithelium. In a pathway analysis, the genes differentially expressed between IBC and non‐IBC tumors clustered in distinct pathways. We identified multiple pathways related to the endoplasmic stress response that could be functionally significant in IBC. Our findings suggest that the gene expression in the tumor stroma may play a role in determining the IBC phenotype. © 2007 Wiley‐Liss, Inc.

[1]  R. Tibshirani,et al.  Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[2]  K. Gish,et al.  Candidate tumor-suppressor genes on chromosome arm 8p in early-onset and high-grade breast cancers , 2004, Oncogene.

[3]  R. Salunga,et al.  Gene expression profiles of human breast cancer progression , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[4]  Howard Y. Chang,et al.  Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[5]  Peter Horak,et al.  Five genes from chromosomal band 8p22 are significantly down‐regulated in ovarian carcinoma , 2005, Cancer.

[6]  J. Chirgwin,et al.  A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[7]  Yudong D. He,et al.  Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.

[8]  M. Morrow,et al.  Surgical aspects of inflammatory breast cancer. , 2005, Breast disease.

[9]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[10]  Identifying pre-post chemotherapy differences in gene expression in breast tumours: a statistical method appropriate for this aim , 2002, British Journal of Cancer.

[11]  S. Steinberg,et al.  Microvessel density, expression of estrogen receptor alpha, MIB-1, p53, and c-erbB-2 in inflammatory breast cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[12]  Julie E Goodman,et al.  Association of breast cancer outcome with status of p53 and MDM2 SNP309. , 2006, Journal of the National Cancer Institute.

[13]  Jing Li,et al.  Analysis of differential gene expression patterns in colon cancer and cancer stroma using microdissected tissues. , 2005, Gastroenterology.

[14]  Van,et al.  A gene-expression signature as a predictor of survival in breast cancer. , 2002, The New England journal of medicine.

[15]  M. Reth,et al.  The adaptor protein SLP-65 acts as a tumor suppressor that limits pre-B cell expansion , 2003, Nature Immunology.

[16]  R. Tibshirani,et al.  Diagnosis of multiple cancer types by shrunken centroids of gene expression , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[17]  Carsten O. Peterson,et al.  Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. , 2001, Cancer research.

[18]  K. Tryggvason,et al.  Laminin-5 is a marker of invading cancer cells in some human carcinomas and is coexpressed with the receptor for urokinase plasminogen activator in budding cancer cells in colon adenocarcinomas. , 1995, Cancer research.

[19]  Luc Y Dirix,et al.  Increased Angiogenesis and Lymphangiogenesis in Inflammatory versus Noninflammatory Breast Cancer by Real-Time Reverse Transcriptase-PCR Gene Expression Quantification , 2004, Clinical Cancer Research.

[20]  Rosette Lidereau,et al.  Molecular Profiling of Inflammatory Breast Cancer , 2004, Clinical Cancer Research.

[21]  S. Merajver,et al.  Persistent E-Cadherin Expression in Inflammatory Breast Cancer , 2001, Modern Pathology.

[22]  S. Gruber,et al.  Anti-oncogenic role of the endoplasmic reticulum differentially activated by mutations in the MAPK pathway , 2006, Nature Cell Biology.

[23]  R. Tibshirani,et al.  Significance analysis of microarrays applied to the ionizing radiation response , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[24]  Tilman Brummer,et al.  Positive regulation of immune cell function and inflammatory responses by phosphatase PAC-1 , 2006, Nature Immunology.

[25]  S. Ambs,et al.  Inflammation and IGF‐I activate the Akt pathway in breast cancer , 2007, International journal of cancer.

[26]  Hiroyuki Yamamoto,et al.  Expression of the g 2 Chain of Laminin-5 at the Invasive Front Is Associated with Recurrence and Poor Prognosis in Human Esophageal Squamous Cell Carcinoma 1 , 2001 .

[27]  A. Buzdar,et al.  Inflammatory breast carcinoma incidence and survival , 1998, Cancer.

[28]  H. Kleinman,et al.  Endogenous osteonectin/SPARC/BM-40 expression inhibits MDA-MB-231 breast cancer cell metastasis. , 2005, Cancer research.

[29]  L. Kiesel,et al.  Expression of endothelin-1, endothelin-A, and endothelin-B receptor in human breast cancer and correlation with long-term follow-up. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[30]  P. Dam,et al.  Identification of cell-of-origin breast tumor subtypes in inflammatory breast cancer by gene expression profiling , 2006, Breast Cancer Research and Treatment.

[31]  E. van Marck,et al.  Nuclear factor-kappaB signature of inflammatory breast cancer by cDNA microarray validated by quantitative real-time reverse transcription-PCR, immunohistochemistry, and nuclear factor-kappaB DNA-binding. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[32]  N. Crawford,et al.  Germ line polymorphism in metastatic progression. , 2006, Cancer research.

[33]  S. Hilsenbeck,et al.  Molecular Heterogeneity of Inflammatory Breast Cancer: A Hyperproliferative Phenotype , 2006, Clinical Cancer Research.

[34]  B. A. Ballif,et al.  Interaction of cyclooxygenases with an apoptosis- and autoimmunity-associated protein. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[35]  F. Antonicelli,et al.  The small leucine-rich proteoglycan lumican inhibits melanoma progression. , 2004, Experimental cell research.

[36]  Peter H Watson,et al.  Reduced expression of the small leucine-rich proteoglycans, lumican, and decorin is associated with poor outcome in node-negative invasive breast cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[37]  S. Ménard,et al.  SEL1L a multifaceted protein playing a role in tumor progression , 2006, Journal of cellular physiology.

[38]  I. M. Neiman,et al.  [Inflammation and cancer]. , 1974, Patologicheskaia fiziologiia i eksperimental'naia terapiia.

[39]  P. Levine,et al.  Inflammatory breast cancer: the experience of the surveillance, epidemiology, and end results (SEER) program. , 1985, Journal of the National Cancer Institute.

[40]  Hiroyuki Yamamoto,et al.  Expression of the γ2 Chain of Laminin-5 at the Invasive Front Is Associated with Recurrence and Poor Prognosis in Human Esophageal Squamous Cell Carcinoma , 2001 .

[41]  Ming Yi,et al.  WholePathwayScope: a comprehensive pathway-based analysis tool for high-throughput data , 2006, BMC Bioinformatics.

[42]  Daniel Birnbaum,et al.  Gene expression profiling identifies molecular subtypes of inflammatory breast cancer. , 2005, Cancer research.

[43]  S. Devesa,et al.  Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute. , 2005, Journal of the National Cancer Institute.

[44]  K. Sekiguchi,et al.  Laminin gamma2-chain fragment in the circulation: a prognostic indicator of epithelial tumor invasion. , 2003, Cancer research.

[45]  S. Nasim,et al.  Evaluation of a linear amplification method for small samples used on high-density oligonucleotide microarray analysis. , 2004, Analytical biochemistry.

[46]  A. Howell,et al.  Occurrence of a fetal fibroblast phenotype in familial breast cancer , 1986, International journal of cancer.

[47]  Andrea Bild,et al.  Gene Expression Profiles of Multiple Breast Cancer Phenotypes and Response to Neoadjuvant Chemotherapy , 2006, Clinical Cancer Research.

[48]  Dennis C. Sgroi,et al.  Stromal Fibroblasts Present in Invasive Human Breast Carcinomas Promote Tumor Growth and Angiogenesis through Elevated SDF-1/CXCL12 Secretion , 2005, Cell.

[49]  Philip M. Long,et al.  Breast cancer classification and prognosis based on gene expression profiles from a population-based study , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[50]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[51]  S. Merajver,et al.  Molecular biology of breast cancer metastasis: Inflammatory breast cancer: clinical syndrome and molecular determinants , 2000, Breast Cancer Research.

[52]  S. Swain,et al.  Clinical aspects of inflammatory breast cancer. , 2005, Breast disease.

[53]  S. Merajver,et al.  A novel putative low-affinity insulin-like growth factor-binding protein, LIBC (lost in inflammatory breast cancer), and RhoC GTPase correlate with the inflammatory breast cancer phenotype. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[54]  I. Kurochkin,et al.  ALEX1, a novel human armadillo repeat protein that is expressed differentially in normal tissues and carcinomas. , 2001, Biochemical and biophysical research communications.

[55]  F. Bertucci,et al.  Gene Expression Profiling for Molecular Characterization of Inflammatory Breast Cancer and Prediction of Response to Chemotherapy , 2004, Cancer Research.

[56]  Wei Wang,et al.  A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. , 2004, Cancer cell.

[57]  T. Brabletz,et al.  Expression of the Invasion Factor Laminin γ2 in Colorectal Carcinomas Is Regulated by β-Catenin , 2001 .

[58]  Luc Y. Dirix,et al.  Distinct Molecular Signature of Inflammatory Breast Cancer by cDNA Microarray Analysis , 2005, Breast Cancer Research and Treatment.

[59]  K J Millen,et al.  The ZIC gene family in development and disease , 2005, Clinical genetics.